Treatment emergent peripheral neuropathy in the CASSIOPEIA trial

Cathelijne Fokkema, Phillipe Moreau, Bronno van der Holt, Jérôme Lambert, Mark van Duin, Ruth Wester, Joost L.M. Jongen, Pieter A. van Doorn, Sophie Godet, Kon Siong Jie, Olivier Fitoussi, Michel Delforge, Awa Keita-Manta, Odile Luycx, Tom Cupedo, Niels W.C.J. van de Donk, Sonja Zweegman, Jessica T. Vermeulen, Pieter Sonneveld, Annemiek Broijl*

*Corresponding author for this work

Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

2 Citations (Scopus)
15 Downloads (Pure)
Original languageEnglish
Pages (from-to)1726-1730
Number of pages5
JournalHaematologica
Volume107
Issue number7
DOIs
Publication statusPublished - Jul 2022

Bibliographical note

Funding Information:
PM receives honoraria from AbbVie, Amgen, Celgene, Janssen, and Takeda, is a member of AbbVie's, Amgen's, Celgene's, Janssen Pharmaceuticals', and Takeda's Board of Directors or advisory committees, and is a member of AbbVie's, Amgen's, Celgene's, and Janssen Pharmaceuticals Speakers Bureau. JL is employed by Janssen Pharmaceuticals. JJ received honoraria from Amgen and Mundipharma. MD received speaker honoraria from Amgen, BMS Celgene, Janssen, Takeda, Sanofi. NWCJvdD is a consultant for Amgen, Bayer, Bristol-Myers Squibb, Celgene, Janssen Pharmaceuticals, Novartis, Servier, and Takeda and receives research funding from Amgen, Bristol-Myers Squibb, Celgene, Janssen Pharmaceuticals, and Novartis. SZ receives research funding from and is a member of the Board of Directors or advisory committees for Celgene, Janssen Pharmaceuticals, and Takeda. JV is employed by and owns equity in Janssen Pharmaceuticals. PS receives honoraria and research funding from Amgen, Celgene, Janssen Pharmaceuticals, Karyopharm, and Takeda and receives researching funding from Skyline. AB receives honoraria from Amgen, Bristol-Myers Squibb, Celgene, and Janssen Pharmaceuticals. All other authors declare no competing interests.

Funding Information:
This study was supported by Intergroupe Francophone du Myélome (IFM), the Dutch-Belgian Cooperative Trial Group for Hematology Oncology (HOVON) in collaboration with Janssen Research & Development and the Dutch Cancer Society (KWF).

Cite this